Thalidomide in Multiple Myeloma:
current status and future prospects

Compiled by:

Jamie D. Cavenagh MD MRCP MRCPath, Senior Lecturer (Hon. Consultant) in Haematology, St Bartholomew's and The Royal London School of Medicine and Dentistry

and

Heather Oakervee MRCP MRCPath, Clinical Research Fellow, St Bartholomew's and The Royal London School of Medicine and Dentistry

On behalf of the UK Myeloma Forum and the BCSH Haematology/Oncology Task Force

Correspondence to:

Dr Jamie Cavenagh, Department of Haematology, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE

Telephone: 020 7601 8202  Fax: 020 7601 8200
E-mail: j.d.cavenagh@qmul.ac.uk

Table of Contents

1. Introduction
2. Thalidomide treatment
• Thalidomide as a single agent
• Thalidomide analogues
• Thalidomide and dexmethasone
• Thalidomide and chemotherapy
3. Venous thromboembolism
4. Other side effects
5. Summary and conclusions
6. References

Continue here: 1. Introduction >>